- Home
- SLDP vs EPIX Comparison
SLDP vs EPIX Comparison
Compare SLDP & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- EPIX
- Stock Information
- Founded
- SLDP 2011
- EPIX 2009
- Country
- SLDP United States
- EPIX Canada
- Employees
- SLDP 260
- EPIX N/A
- Industry
- SLDP Electrical Products
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- EPIX Health Care
- Exchange
- SLDP Nasdaq
- EPIX Nasdaq
- Market Cap
- SLDP 394.6M
- EPIX 75.9M
- IPO Year
- SLDP N/A
- EPIX N/A
- Fundamental
- Price
- SLDP $2.58
- EPIX $1.69
- Analyst Decision
- SLDP Buy
- EPIX Hold
- Analyst Count
- SLDP 2
- EPIX 3
- Target Price
- SLDP $1.50
- EPIX $2.00
- AVG Volume (30 Days)
- SLDP 8.5M
- EPIX 53.5K
- Earning Date
- SLDP 08-05-2025
- EPIX 08-04-2025
- Dividend Yield
- SLDP N/A
- EPIX N/A
- EPS Growth
- SLDP N/A
- EPIX N/A
- EPS
- SLDP N/A
- EPIX N/A
- Revenue
- SLDP $20,202,000.00
- EPIX N/A
- Revenue This Year
- SLDP $28.39
- EPIX N/A
- Revenue Next Year
- SLDP $38.07
- EPIX N/A
- P/E Ratio
- SLDP N/A
- EPIX N/A
- Revenue Growth
- SLDP 3.22
- EPIX N/A
- 52 Week Low
- SLDP $0.68
- EPIX $1.40
- 52 Week High
- SLDP $2.70
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- SLDP 70.40
- EPIX 46.72
- Support Level
- SLDP $2.22
- EPIX $1.68
- Resistance Level
- SLDP $2.62
- EPIX $1.75
- Average True Range (ATR)
- SLDP 0.22
- EPIX 0.04
- MACD
- SLDP 0.04
- EPIX -0.00
- Stochastic Oscillator
- SLDP 95.00
- EPIX 32.58
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.